ALBA 4D
ALBA 4D 1.1
Medicalexpo
ALBA 4D 1.3
Medicalexpo
ALBA 4D 1.5
ALBA 4D 1.6
ALBA4D 1
ALBA4D 2
ALBA4D 3
ALBA4D 4
ALBA4D 5
ALBA4D 6
ALBA4D 7
ALBA4D 8
ALBA4D 9
ALBA4D 10
ALBA4D 11
ALBA4D 12
ALBA 4D 1.1
Medicalexpo
ALBA 4D 1.3
Medicalexpo
ALBA 4D 1.5
ALBA 4D 1.6
ALBA4D 1
ALBA4D 2
ALBA4D 3
ALBA4D 4
ALBA4D 5
ALBA4D 6
ALBA4D 7
ALBA4D 8
ALBA4D 9
ALBA4D 10
ALBA4D 11
ALBA4D 12

ALBA 4D

Hyperthermia (HT), heating tumors in the range 41-43°C, is a powerful radio and chemosensitizer. The effectiveness of HT as well as its safety, in combination with radiotherapy and chemotherapy, has already been proven in phase III clinical trials [1, 2] particularly in patients with very large or very advanced stages of cancer and recurrent tumors. HT enhances the effect of radiotherapy on the tumor, without additional toxicity for healthy tissues, thanks to of three synergistic mechanisms:

INHIBITION OF DNA REPAIR

HT enhances the effectiveness of radiotherapy by inhibiting repair of DNA damage.

REOXYGENATION

HT increases tissue perfusion resulting in reoxygenation, thereby reducing hypoxia and increasing radiosensitivity.
With regards to chemotherapy, hyperthermia targets its action within the heated tumor region without affecting systemic toxicity. It has also been shown that local hyperthermia has the capability of inducing systemic anti-tumor immune responses.

DIRECT CELL KILLING

HT selectively kills radioresistant hypoxic tumor cells.

The information on this site is intended for healthcare professionals only. By clicking ‘OK’, you confirm that you belong to this category in accordance with the Medical Device Authority Regulations. Click ‘Cancel’ to return to your previous browser page.